Ovarian Cancer Audit Feasibility Pilot: Outputs

Disease Profile in England: Incidence, mortality, stage and survival for ovary, fallopian tube and primary peritoneal carcinomas

The first report from the Ovarian Cancer Audit Feasibility Pilot was the Disease Profile, covering incidence, mortality, stage and survival, published January 2020.

Main findings:

  • The incidence rate of ovary, fallopian tube and primary peritoneal carcinomas in England has remained reasonably stable since 2001.
  • Incidence and mortality rates vary among CCGs and Cancer Alliances, with variation beyond what might be expected by random chance, suggesting that there may be genuine differences between areas.
  • The proportions of patients diagnosed at early and late stages vary considerably around the country; some of this variability is likely due to data completeness but other factors should also be considered.
  • Completeness of stage data varies by geography; there is some room for improvement which would lead to better data quality for reporting.
  • Survival of patients with ovary, fallopian tube and primary peritoneal carcinomas has been improving since 2001. Improving one-year survival may reflect progress in diagnosing the disease sooner, with increased awareness of the symptoms amongst women and primary care practitioners, and improved diagnostic pathways, enabling more women to be diagnosed while still well enough to undergo treatment. Increased 5-year survival may reflect improvements in surgical and chemotherapy treatments. Assessment of geographic variation in survival rates may help to identify areas of best practice and improve the outlook for all patients.

PDF report and supporting tables (Figure 1 of PDF report corrected Feb 2020).

Geographic variation in ovarian, fallopian tube and primary peritoneal cancer treatment in England

Given the disparity in ovarian cancer survival highlighted in the first report, this second output looks to see whether some of this variation may be attributable to differences in clinical practice across regions of England.

Results indicate that the probability of accessing surgery and chemotherapy varies across England, even after accounting for differences in patient and tumour characteristics.

These findings indicate an opportunity for identifying examples of best practice that could be disseminated to Cancer Alliances where treatment probabilities are lower, leading to improvements in therapy and better outcomes for women with ovarian cancer. 

PDF report

Data completeness reports

Data completeness reports for certain key data items for ovarian cancer are available to members of gynae-oncology MDTs and other individuals within trusts and cancer alliances who have reason to access the data via the Cancerstats2 website: https://cancerstats.ndrs.nhs.uk. Access can be requested via a button on that page.